BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 22677129)

  • 1. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia.
    Tanaka S; Miyagi S; Sashida G; Chiba T; Yuan J; Mochizuki-Kashio M; Suzuki Y; Sugano S; Nakaseko C; Yokote K; Koseki H; Iwama A
    Blood; 2012 Aug; 120(5):1107-17. PubMed ID: 22677129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
    Neff T; Sinha AU; Kluk MJ; Zhu N; Khattab MH; Stein L; Xie H; Orkin SH; Armstrong SA
    Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5028-33. PubMed ID: 22396593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.
    Thiel AT; Feng Z; Pant DK; Chodosh LA; Hua X
    Haematologica; 2013 Jun; 98(6):918-27. PubMed ID: 23349306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetraspanin Family Member, CD82, Regulates Expression of EZH2 via Inactivation of p38 MAPK Signaling in Leukemia Cells.
    Nishioka C; Ikezoe T; Yang J; Yokoyama A
    PLoS One; 2015; 10(5):e0125017. PubMed ID: 25955299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells.
    Fiskus W; Wang Y; Sreekumar A; Buckley KM; Shi H; Jillella A; Ustun C; Rao R; Fernandez P; Chen J; Balusu R; Koul S; Atadja P; Marquez VE; Bhalla KN
    Blood; 2009 Sep; 114(13):2733-43. PubMed ID: 19638619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
    Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
    Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model.
    Danis E; Yamauchi T; Echanique K; Haladyna J; Kalkur R; Riedel S; Zhu N; Xie H; Bernt KM; Orkin SH; Armstrong SA; Neff T
    Exp Hematol; 2015 Nov; 43(11):930-935.e6. PubMed ID: 26118502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
    Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
    Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16.
    Ueda K; Yoshimi A; Kagoya Y; Nishikawa S; Marquez VE; Nakagawa M; Kurokawa M
    Cancer Sci; 2014 May; 105(5):512-9. PubMed ID: 24612037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.
    Fujita S; Honma D; Adachi N; Araki K; Takamatsu E; Katsumoto T; Yamagata K; Akashi K; Aoyama K; Iwama A; Kitabayashi I
    Leukemia; 2018 Apr; 32(4):855-864. PubMed ID: 28951561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line.
    Karanikolas BD; Figueiredo ML; Wu L
    Mol Cancer Res; 2009 Sep; 7(9):1456-65. PubMed ID: 19723877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia.
    Simon C; Chagraoui J; Krosl J; Gendron P; Wilhelm B; Lemieux S; Boucher G; Chagnon P; Drouin S; Lambert R; Rondeau C; Bilodeau A; Lavallée S; Sauvageau M; Hébert J; Sauvageau G
    Genes Dev; 2012 Apr; 26(7):651-6. PubMed ID: 22431509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant Expression of
    de Souza Fernandez T; Fonseca Alvarenga T; Almeida Antônio de Kós E; Lamim Lovatel V; Tavares RC; da Costa ES; de Souza Fernandez C; Abdelhay E
    Biomed Res Int; 2019; 2019():3176565. PubMed ID: 31886200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IKZF2 Drives Leukemia Stem Cell Self-Renewal and Inhibits Myeloid Differentiation.
    Park SM; Cho H; Thornton AM; Barlowe TS; Chou T; Chhangawala S; Fairchild L; Taggart J; Chow A; Schurer A; Gruet A; Witkin MD; Kim JH; Shevach EM; Krivtsov A; Armstrong SA; Leslie C; Kharas MG
    Cell Stem Cell; 2019 Jan; 24(1):153-165.e7. PubMed ID: 30472158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth.
    Sasaki H; Setoguchi T; Matsunoshita Y; Gao H; Hirotsu M; Komiya S
    Oncol Rep; 2010 Mar; 23(3):677-84. PubMed ID: 20127006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the enhancer of zeste homologue 2 in medulloblastoma.
    Alimova I; Venkataraman S; Harris P; Marquez VE; Northcott PA; Dubuc A; Taylor MD; Foreman NK; Vibhakar R
    Int J Cancer; 2012 Oct; 131(8):1800-9. PubMed ID: 22287205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma.
    Vo BT; Li C; Morgan MA; Theurillat I; Finkelstein D; Wright S; Hyle J; Smith SMC; Fan Y; Wang YD; Wu G; Orr BA; Northcott PA; Shilatifard A; Sherr CJ; Roussel MF
    Cell Rep; 2017 Mar; 18(12):2907-2917. PubMed ID: 28329683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
    Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
    Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SUMOylation of sPRDM16 promotes the progression of acute myeloid leukemia.
    Dong S; Chen J
    BMC Cancer; 2015 Nov; 15():893. PubMed ID: 26559765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.